BCL2 and lymphoid leukemia: We decided to evaluate the AZD-7762/BCL-2 inhibitor combination further, as the US FDA has approved BCL-2 inhibitor venetoclax/ABT 199 for subsets of lymphocytic leukemia, and clinical trials are underway to evaluate CHK1 inhibitors.